Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
US10493139B2 · kind B2 · utility
3Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 22, 2018 |
| Grant date | Dec 3, 2019 |
| Priority date | — |
| Expiry date | Jan 22, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/43
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.